Skip to main content

Table 5 Safety analysis

From: Impact of rifampicin dose in bone and joint prosthetic device infections due to Staphylococcus spp: a retrospective single-center study in France

  Total Low-dose Intermediate-dose High-dose
AE occurrence, n (%)
 Yes 106 (25.8) 5 (18.5) 81 (25.4) 20 (30.8)
 No 281 (68.4) 18 (66.7) 220 (69) 43 (66.2)
 Unknown 24 (5.8) 4 (14.8) 18 (5.6) 2 (3.1)
Type of AE, n (%)
 Digestive 51 (48.1) 2 (40) 36 (44.4) 12 (60)
 Hepatic 12 (11.3) 2 (40) 11 (13.6) 0 (0)
 Cutaneous 11 (10.4) 0 (0) 8 (9.9) 2 (10)
 Renal 3 (2.8) 0 (0) 2 (2.5) 1 (5)
 Hematological 2 (1.9) 0 (0) 2 (2.5) 0 (0)
 General 1 (0,94) 0 (0) 1 (1,2) 0 (0)
 Neurologic 1 (0,94) 0 (0) 1 (1,2) 0 (0)
  > 1 AE types 23 (21,8) 1 (20) 17 (20,9) 4 (20)
 Not specified 1 (0,94) 0 (0) 1 (1,2) 1 (5)
 Unknown 1 (0,94) 0 (0) 2 (2,5) 0 (0)
AE severity grade, n (%)
 I – II 75 (70.8) 3 (60) 53 (65.4) 16 (80)
 III – IV 15 (14.2) 2 (40) 10 (12.3) 2 (10)
 Unknown 16 (15) 0 (0) 18 (22.2) 2 (10)
AE consequences on patient management
 Antibiotic change 62 (58.5) 5 (100) 50 (61.7) 7 (35)
 Rifampicin continuation 32 (30.2) 0 (0) 20 (24.7) 11 (55)
 Galenic change 6 (5.7) 0 (0) 4 (4.9) 2 (10)
 Dosage decrease 2 (1.9) 0 (0) 2 (2.5) 0 (0)
 Antibiotic discontinuation 4 (3.8) 0 (0) 4 (4.9) 0 (0)
 Unknown 0 (0) 0 (0) 1 (1.2) 0 (0)
\